Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Myeloma
•
Hematology
•
Transplant nephrology
•
Multiple Myeloma
Would you consider pursuing renal transplantation in a patient with multiple myeloma?
Related Questions
What clinical or logistical factors influence your choice of anti-CD38 antibody in first line treatment of Multiple Myeloma?
How does one approach maintenance treatment in transplant ineligible patients with newly diagnosed multiple myeloma?
Under what circumstances is it okay to initiate treatment for suspected multiple myeloma without a bone marrow biopsy?
With the recent approvals of CAR-T for second-line therapy in myeloma, does this change your approach to use of consolidative autologous transplant or autologous transplant as second line therapy?
What is your current practice for de-escalation of frequency of administration of bispecific antibodies among responders in patients with relapsed/refractory multiple myeloma?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
Is there a role for CRS prophylaxis with tocilizumab during bispecific T cell engager initiation for myeloma?
Should you consider thromboprophylaxis, even for low-dose lenalidomide maintenance, post-autologous transplantation?
How would you approach management and monitoring of AL amyloidosis with isolated renal involvement?
How do you approach second-line options for relapsed myeloma after front-line quadruplet therapy?
